Command Palette

Search for a command to run...

venmax-drugs-and-pharmaceuticals

20.95+4.96%
Market Cap
₹0.00 Cr
Stock P/E
0.00
ROCE
0.00%
ROE
0.00%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Venmax Drugs And Pharmaceuticals Ltd. shows no growth and profitability metrics, positioning it poorly against peers in the pharmaceuticals sector. Notably, peers like Sun Pharmaceutical Industries and Dr. Reddy's Laboratories demonstrate strong growth, profitability, and efficient operations, making them sector leaders. Venmax, with its significantly high valuation metrics and lack of profitability, appears overvalued and financially weak compared to its well-performing counterparts.

Key Points
  • Venmax has zero revenue growth and no profitability metrics, making it a laggard.
  • Sun Pharmaceutical and Dr. Reddy's lead in profitability with high ROE and EPS.
  • Cipla and Mankind Pharma show strong growth and reasonable valuations, making them attractive picks.
Top Performers
Sun Pharmaceutical Industries Ltd.

Highest revenue growth (YoY) at 8.42% and strong ROE of 16.13%.

Dr. Reddy's Laboratories Ltd.

Consistent profitability with an ROE of 21.76% and a PE ratio of 15.5, indicating good value.

Cipla Ltd.

Strong revenue growth of 13.28% and low PE ratio of 23.73, making it a solid value pick.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.